<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00420615</url>
  </required_header>
  <id_info>
    <org_study_id>CEPO906A2123</org_study_id>
    <nct_id>NCT00420615</nct_id>
  </id_info>
  <brief_title>Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies</brief_title>
  <official_title>An Open Label Phase I Study to Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the potential inhibitory effects of patupilone on
      metabolism using midazolam and omeprazole as the respective probe drugs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effects of patupilone on the pharmacokinetics of midazolam in patients with advanced malignancies.</measure>
    <time_frame>Day 1 (0.5h, 1h, 1.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h), Day 29 (0.5h, 1h, 1.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the effects of patupilone on the pharmacokinetics of omeprazole in patients with advanced malignancies</measure>
    <time_frame>Day 1 (0.33h (20m), 0.67h (40m), 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of Patupilone when administered concomitantly with midazolam in patients with advanced malignancies.</measure>
    <time_frame>at each visit (week 1, week 2, week 5, and end of study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of Patupilone when administered concomitantly with omeprazole in patients with advanced malignancies.</measure>
    <time_frame>at each visit (week 1, week 2, week 5, and end of study)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Patupilone and Omeprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patupiloe + omeprazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patupilone + midalzolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patupilone + midalzolam</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patupilone and Omeprazole</intervention_name>
    <arm_group_label>Patupilone and Omeprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patupilone + Midalzolam</intervention_name>
    <arm_group_label>patupilone + midalzolam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male or female patients 18 years or older

          -  Histologically documented advanced solid tumor, who have failed standard systemic
             therapy, or for whom standard systemic therapy does not exist

          -  Life expectancy of 3 months or more

          -  Patients with adequate hematologic parameters

        Exclusion criteria:

          -  Hypersensitivity to midazolam or omeprazole or related compounds

          -  Female patients who are pregnant or breast-feeding.

          -  Patients with a severe and/or uncontrolled medical disease

          -  Patients with a known diagnosis of human immunodeficiency virus (HIV) infection

          -  Patients having received an investigational agent within 30 days prior to study entry

        Other protocol defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmeceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2007</study_first_submitted>
  <study_first_submitted_qc>January 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2007</study_first_posted>
  <last_update_submitted>April 23, 2012</last_update_submitted>
  <last_update_submitted_qc>April 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>EPO906</keyword>
  <keyword>Patupilone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Epothilone B</mesh_term>
    <mesh_term>Epothilones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

